Vertex Pharmaceuticals Inc. (VRTX)

176.23
NASDAQ : Health Technology
Prev Close 177.72
Day Low/High 175.38 / 180.25
52 Wk Low/High 151.80 / 195.81
Avg Volume 1.17M
Exchange NASDAQ
Shares Outstanding 257.04M
Market Cap 45.68B
EPS 8.20
P/E Ratio 20.81
Div & Yield N.A. (N.A)
Vertex Awards $1 Million In Grants To 18 Non-profit Organizations To Advance Initiatives For People Living With Cystic Fibrosis

Vertex Awards $1 Million In Grants To 18 Non-profit Organizations To Advance Initiatives For People Living With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has awarded the company's 2016 Cystic Fibrosis (CF) Circle of Care grants, totaling approximately $1 million, to 18 non-profit...

10 Big CEOs Who Make Way Too Much Money

10 Big CEOs Who Make Way Too Much Money

CEO compensation is a hot-button issue for investors, labor unions, the public and now -- given the election year -- for politicians too.

Vertex To Present At Upcoming Investor Conferences

Vertex To Present At Upcoming Investor Conferences

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it will present at the Leerink Healthcare Conference in New York, NY on Thursday, February 11 th at 11:10 a.

Vertex Receives Complete Response Letter From U.S. FDA For Use Of KALYDECO® (ivacaftor) In People With Cystic Fibrosis Ages 2 And Older With One Of 23 Residual Function Mutations

Vertex Receives Complete Response Letter From U.S. FDA For Use Of KALYDECO® (ivacaftor) In People With Cystic Fibrosis Ages 2 And Older With One Of 23 Residual Function Mutations

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it received a Complete Response Letter from the U.

Analysts' Actions -- Bristol-Myers, Chipotle, Monster Beverage, Vertex Pharmaceuticals and More

Analysts' Actions -- Bristol-Myers, Chipotle, Monster Beverage, Vertex Pharmaceuticals and More

Here are Monday's top research calls, including upgrades for Monster Beverage, Vertex Pharmaceuticals and Chipotle Mexican Grill, and a downgrade for Bristol-Myers Squibb.

Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?

Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?

Biotech news and observations to start the week.

Here Are the 5 Worst-Performing Stocks in the S&P 500 in 2016

Here Are the 5 Worst-Performing Stocks in the S&P 500 in 2016

The S&P 500 Index slumped 5.1% in January, despite Friday's positive performance. Here are the S&P's worst performers to date.

Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Loser Stock

Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Loser Stock

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a post-market laggard candidate

Vertex Reports Full-Year And Fourth Quarter 2015 Financial Results

Vertex Reports Full-Year And Fourth Quarter 2015 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended December 31, 2015.

Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis For People Ages 12 And Older With Two Copies Of The F508del Mutation

Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis For People Ages 12 And Older With Two Copies Of The F508del Mutation

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has approved PrORKAMBI ® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in...

Biotech String: Editas IPO Terms, Rooting for Shkreli in DC

Biotech String: Editas IPO Terms, Rooting for Shkreli in DC

Biotech news and observations to start the week.

Vertex Pharmaceuticals (VRTX) Showing Signs Of Perilous Reversal Today

Vertex Pharmaceuticals (VRTX) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a "perilous reversal" (up big yesterday but down big today) candidate

Here Are the 10 Worst S&P 500 Stocks So Far in 2016

Here Are the 10 Worst S&P 500 Stocks So Far in 2016

The markets on Wednesday took another deep dive, plunging more than 300 points. These 10 S&P 500 companies are the worst performers to date.

3 Stocks Pulling The Drugs Industry Downward

3 Stocks Pulling The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

A Lack of News and Buzz at 'JPM16' Sinks Biotech Stocks

A Lack of News and Buzz at 'JPM16' Sinks Biotech Stocks

Biotech stocks large and small were plummeting as 2016's painful start began to turn torturous.

Vertex Takes a Pass on 2016 Orkambi Cystic Fibrosis Sales Guidance

Vertex Takes a Pass on 2016 Orkambi Cystic Fibrosis Sales Guidance

Vertex presents to investors on Monday at the J.P. Morgan Healthcare Conference.

Vertex Outlines 2016 Business Priorities To Support The Discovery And Development Of New Transformative Medicines For The Treatment Of Cystic Fibrosis And Other Serious Diseases

Vertex Outlines 2016 Business Priorities To Support The Discovery And Development Of New Transformative Medicines For The Treatment Of Cystic Fibrosis And Other Serious Diseases

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today outlined key 2016 business priorities to support the company's efforts to discover and develop medicines for people with cystic fibrosis (CF) and other serious...

5 Toxic Stocks to Sell in January

5 Toxic Stocks to Sell in January

It's time to unload these toxic stocks from your portfolio.

Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2015 Financial Results

Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2015 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 34 th Annual J.

Sell These 6 Biotech Stocks Now Before It's Too Late

Sell These 6 Biotech Stocks Now Before It's Too Late

Biotech stocks are set to outperform in 2015, but here are six stocks that investors should steer clear of in 2016.

J.P. Morgan's 53 Top Stock Picks for 2016

J.P. Morgan's 53 Top Stock Picks for 2016

J.P. Morgan analysts identified the most compelling investments for 2016 across growth, value, income-oriented, short and market-neutral strategies. Below is the list of stocks that made the analysts' top picks.

Today's Dead Cat Bounce Stock Is Vertex Pharmaceuticals (VRTX)

Today's Dead Cat Bounce Stock Is Vertex Pharmaceuticals (VRTX)

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a "dead cat bounce" (down big yesterday but up big today) candidate

3 Drugs Stocks Dragging The Industry Down

3 Drugs Stocks Dragging The Industry Down

TheStreet highlights 3 stocks pushing the drugs industry lower today.

'Mad Money' Lightning Round: Buy Kroger, It's Terrific

'Mad Money' Lightning Round: Buy Kroger, It's Terrific

Cramer says buy Arris Group and Eaton but avoid Micron Technology.

Jim Cramer's 'Mad Money' Recap: These Retailers Will Survive the Amazon Express

Jim Cramer's 'Mad Money' Recap: These Retailers Will Survive the Amazon Express

Amazon is growing at the expense of other retailers, Cramer says. But there are still some companies he thinks are worth buying.

Vertex To Present At The Piper Jaffray Healthcare Conference On December 1

Vertex To Present At The Piper Jaffray Healthcare Conference On December 1

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 1 at 11:00 a.

Vertex Appoints Michael J. Parini As Executive Vice President And Chief Legal Officer

Vertex Appoints Michael J. Parini As Executive Vice President And Chief Legal Officer

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Michael J.

Vertex Receives EU Approval For ORKAMBI® (lumacaftor/ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation

Vertex Receives EU Approval For ORKAMBI® (lumacaftor/ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted Marketing Authorization for ORKAMBI ® (lumacaftor/ivacaftor), the first medicine to treat the underlying...

Vertex Receives Two EU Approvals For KALYDECO® (ivacaftor) For People With Cystic Fibrosis

Vertex Receives Two EU Approvals For KALYDECO® (ivacaftor) For People With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has approved expansion of the indication for KALYDECO ® (ivacaftor) to include children ages 2 to 5 with cystic fibrosis...

3 Stocks Raising The Drugs Industry Higher

3 Stocks Raising The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

TheStreet Quant Rating: B (Buy)